Article
Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant.
International journal of clinical oncology - 1 May 2023
Nakai Chikako, Mimaki Sachiyo, Matsushima Koutatsu, Shinozaki Eiji, Yamazaki Kentaro, Muro Kei, Yamaguchi Kensei, Nishina Tomohiro, Yuki Satoshi, Shitara Kohei, Bando Hideaki, Suzuki Yutaka, Akagi Kiwamu, Nomura Shogo, Fujii Satoshi, Sugiyama Masaya, Nishida Nao, Mizokami Masashi, Koh Yasuhiro, Koshizaka Takuya, Okada Hideki, Abe Yukiko, Ohtsu Atsushi, Yoshino Takayuki, Tsuchihara Katsuya
Abstract excerpt
BACKGROUND: Oncogenic mutations in BRAF genes are found in approximately 5-10% of colorectal cancers. The majority of BRAF mutations are located within exons 11-15 of the catalytic kinase domains, with BRAF V600E accounting for more than 80% of the observed BRAF mutations. Sensitivity to BRAF- and mitogen-activated protein kinase (MEK) inhibitors varies depending on BRAF mutations and tumor cell types....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.